Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to ritlecitinib with or without narrow-band UVB add-on therapy in patients with active nonsegmental vitiligo: results from a phase 2b extension study.
Yamaguchi Y, Peeva E, Adiri R, Ghosh P, Napatalung L, Hamzavi I, Pandya AG, Shore RN, Ezzedine K, Guttman-Yassky E. Yamaguchi Y, et al. Among authors: pandya ag. J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03381-4. doi: 10.1016/j.jaad.2024.11.064. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39709084
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
Harris JE, Pandya AG, Lebwohl M, Hamzavi IH, Grimes P, Gottlieb AB, Sofen HL, Moore AY, Wang M, Kornacki D, Butler K, Rosmarin D. Harris JE, et al. Among authors: pandya ag. Skin Health Dis. 2024 Aug 7;4(6):e404. doi: 10.1002/ski2.404. eCollection 2024 Dec. Skin Health Dis. 2024. PMID: 39624731 Free PMC article. No abstract available.
Effective and durable repigmentation for stable vitiligo: A randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transplantation.
Hamzavi IH, Ganesan AK, Mahmoud BH, Weiss E, Ahmed AM, Robinson D, Goldman MP, Munavalli G, Kahn SA, Huang V, Waibel J, Desai A, Elbuluk N, Desai S, Pandya AG. Hamzavi IH, et al. Among authors: pandya ag. J Am Acad Dermatol. 2024 Dec;91(6):1104-1112. doi: 10.1016/j.jaad.2024.08.027. Epub 2024 Sep 7. J Am Acad Dermatol. 2024. PMID: 39182674 Free article. Clinical Trial.
Assessing Participants' Experiences with Vitiligo from Patient Interviews.
Pandya AG, Amoloja T, Bibeau K, DiBenedetti D, Kosa K, Butler K, Kornacki D, Ezzedine K. Pandya AG, et al. Dermatol Ther (Heidelb). 2024 Sep;14(9):2467-2478. doi: 10.1007/s13555-024-01241-w. Epub 2024 Aug 5. Dermatol Ther (Heidelb). 2024. PMID: 39103672 Free PMC article.
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.
Passeron T, Ezzedine K, Hamzavi I, van Geel N, Schlosser BJ, Wu X, Huang X, Soliman AM, Rosmarin D, Harris JE, Camp HS, Pandya AG. Passeron T, et al. Among authors: pandya ag. EClinicalMedicine. 2024 May 31;73:102655. doi: 10.1016/j.eclinm.2024.102655. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 38873632 Free PMC article.
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm.
van Geel N, Speeckaert R, Taïeb A, Ezzedine K, Lim HW, Pandya AG, Passeron T, Wolkerstorfer A, Abdallah M, Alomar A, Bae JM, Bekkenk M, Benzekri L, Böhm M, Eleftheriadou V, Esmat S, Ghia D, Goh BK, Grimes P, Gupta S, Hamzavi IH, Harris JE, Oh SH, Huggins R, Katayama I, Lan E, Lee AY, Leone G, Le Poole C, Lui H, Maquignon N, Meurant JM, Monteiro P, Oiso N, Parsad D, Pliszewski G, Raboobee N, Rodrigues M, Rosmarin D, Suzuki T, Tanemura A, Thng S, Xiang F, Zhou Y, Picardo M, Seneschal J. van Geel N, et al. Among authors: pandya ag. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2173-2184. doi: 10.1111/jdv.19451. Epub 2023 Sep 25. J Eur Acad Dermatol Venereol. 2023. PMID: 37746876
169 results